These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17488969)

  • 21. Results of the U.S. ARRIVE 1 registry: 2-year outcomes.
    Kornowski R
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):446-7. PubMed ID: 18819146
    [No Abstract]   [Full Text] [Related]  

  • 22. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
    Gil RJ
    Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
    [No Abstract]   [Full Text] [Related]  

  • 23. The Sirolimus-eluting coronary stent in daily routine practice in Germany: trends in indications over the years. Results from the prospective multi-centre German Cypher Stent Registry.
    Zahn R; Hamm CW; Schneider S; Zeymer U; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Sabin G; Nienaber CA; Pfannebecker T; Senges J;
    Clin Res Cardiol; 2007 Aug; 96(8):548-56. PubMed ID: 17534566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug-coated stents. Where do we stand in 2004?].
    Scheller B
    Z Kardiol; 2004 Sep; 93(9):646-8. PubMed ID: 15365731
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
    Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
    EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
    Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
    N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-eluting stents: immediate and long-term results.
    Korovesis S; Karvouni E; Giazitzoglou E; Katritsis D
    Hellenic J Cardiol; 2005; 46(5):330-5. PubMed ID: 16295941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stent thrombosis in randomized clinical trials of drug-eluting stents.
    Mauri L; Hsieh WH; Massaro JM; Ho KK; D'Agostino R; Cutlip DE
    N Engl J Med; 2007 Mar; 356(10):1020-9. PubMed ID: 17296821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wish list and REALITY: choice of stents and end points for treatment of de novo coronary artery lesions.
    Brener SJ
    JAMA; 2006 Feb; 295(8):937-8. PubMed ID: 16493108
    [No Abstract]   [Full Text] [Related]  

  • 32. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
    Ong AT; Serruys PW; Aoki J; Hoye A; van Mieghem CA; Rodriguez-Granillo GA; Valgimigli M; Sonnenschein K; Regar E; van der Ent M; de Jaegere PP; McFadden EP; Sianos G; van der Giessen WJ; de Feyter PJ; van Domburg RT
    J Am Coll Cardiol; 2005 Apr; 45(7):1135-41. PubMed ID: 15808774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the Food and Drug Administration's Public Health Notification on the adoption of drug-eluting stents.
    Curtis JP; Cohen DJ; Jones PG; Bach RG; Spertus JA; Krumholz HM
    Am J Cardiol; 2007 May; 99(9):1227-9. PubMed ID: 17478147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up.
    Hong MK; Mintz GS; Lee CW; Park DW; Park KM; Lee BK; Kim YH; Song JM; Han KH; Kang DH; Cheong SS; Song JK; Kim JJ; Park SW; Park SJ
    Circulation; 2006 Jan; 113(3):414-9. PubMed ID: 16432073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus- vs. paclitaxel-eluting stents in patients undergoing off-label percutaneous coronary intervention.
    Ruperto C; Capodanno D; Tamburino C
    Int J Cardiol; 2010 Nov; 145(2):299-300. PubMed ID: 19897257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-eluting stents: the panacea for restenosis?
    Lim MC
    Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.